Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Apple Turns 50: From Garage Startup to AI Crossroads 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
BROOKLYN, N.Y., Dec. 28, 2016 -- AzurRx BioPharma, Inc.(NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that Thijs Spoor, the Company’s President and CEO, will be making a company presentation at the Biotech Showcase conference in San Francisco at the Hilton San Francisco Union Square on Monday, January 9th from 2:30-3:00 p.m. PT.
About AzurRx BioPharma, Inc.:
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the Company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The Company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. Additional information on the company can be found at www.azurrx.com.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigations Reform Act of 1995. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the development and testing of our drug candidates, the regulatory approval process, our ability to secure additional financing, the protection of our patent and intellectual property, the success of strategic agreements and relationships, and the potential commercialization of any product we may successfully develop. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
For more Information: AzurRx BioPharma, Inc. 760 Parkside Avenue, Suite 304 Brooklyn, NY 11226 Phone: 646.699.7855 www.azurrx.com [email protected]
